- A notice of allowance has been issued by the Japan Patent Office
- Acceptance of its Israeli patent application no. 261765 was published in the Israel Patents and Designs Journal
- The new patents cover conjugated compounds permitting the delivery of antibodies to the nucleus through the company’s proprietary technology Accum
- The global oncology market size is expected to be worth around US$536.01 billion by 2029
- Defence Therapeutics is a biotechnology company working on engineering the next-generation vaccines and ADC products using its proprietary platform
- Defence Therapeutics Inc. (DTC) opened trading at C$1.68
Defence Therapeutics (DTC) has been granted patents in both Japan and Israel.
A notice of allowance has been issued by the Japan Patent Office for its Japanese patent application no. 2018-568469. In addition, the acceptance of its Israeli patent application no. 261765 was published in the Israel Patents and Designs Journal on 1st August 2022.
The allowance of these new patents covers conjugated compounds permitting the delivery of antibodies to the nucleus through the company’s proprietary technology Accum. Accum further consolidates the company’s patent portfolio on its solution for the precision delivery method for improved intracellular antibody-drug conjugate (ADC) routing. Accum enables ADCs to control intracellular delivery of chemotherapeutic drugs, resulting in superior preclinical anti-tumour activity. By increasing the tumour targeting specificity – due to increased drug accumulation – non-specific toxicity in healthy cells is greatly reduced.
“The Japan and Israel patents constitute an important milestone in protecting and expanding the commercial potential of Accum directly related to our ADC program. Defence is expecting pending key studies results in the near term and will report as they become available. Defence’s commitment to protecting the company’s Accum technology platform innovation is crucial as its ADC development expands. ADC interest continues to increase worldwide being that ADCs are applied in oncology and are advancing rapidly,” says Mr. Plouffe, the CEO of Defence Therapeutics.
According to Precedence Research Predicts, the global oncology market size is expected to be worth around US$536.01 billion by 2029, valued at US$286.04 billion in 2021 and growing at a CAGR of 8.2 per cent from 2021 to 2030. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Rising concern about cancer is one of the major factors driving the market in the oncology market.
The global antibody drug conjugates market size is expected to reach over US$22.87 billion by 2030, registering a CAGR of 16.4 per cent during the forecast period, according to a recent 2022 report by Grand View Research Inc. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive market growth during the forecast period.
Defence Therapeutics is a biotechnology company working on engineering the next-generation vaccines and ADC products using its proprietary platform. The core of the Defence Therapeutics platform is the ACCUM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illnesses such as cancer and infectious diseases.
Defence Therapeutics Inc. (DTC) opened trading at C$1.68.
